As on Thursday, Dianthus Therapeutics Inc (NASDAQ: DNTH) started slowly as it slid -4.47% to $41.63, before settling in for the price of $43.58 at the close. Taking a more long-term approach, DNTH posted a 52-week range of $13.36-$45.46.
The Healthcare sector firm’s twelve-monthly sales growth has been 40.14% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 40.14%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -46.35%. This publicly-traded company’s shares outstanding now amounts to $42.85 million, simultaneously with a float of $35.11 million. The organization now has a market capitalization sitting at $1.78 billion. At the time of writing, stock’s 50-day Moving Average stood at $37.92, while the 200-day Moving Average is $26.08.
Dianthus Therapeutics Inc (DNTH) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Dianthus Therapeutics Inc’s current insider ownership accounts for 18.11%, in contrast to 92.64% institutional ownership. According to the most recent insider trade that took place on Dec 04 ’25, this organization’s CFO & CBO sold 20,000 shares at the rate of 45.18, making the entire transaction reach 903,600 in total value, affecting insider ownership by 0.
Dianthus Therapeutics Inc (DNTH) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
Dianthus Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -46.35% and is forecasted to reach -3.67 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -17.45% through the next 5 years, which can be compared against the 40.14% growth it accomplished over the previous five years trading on the market.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Trading Performance Indicators
Let’s observe the current performance indicators for Dianthus Therapeutics Inc (DNTH). It’s Quick Ratio in the last reported quarter now stands at 17.35. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 579.52.
In the same vein, DNTH’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.49, a figure that is expected to reach -1.07 in the next quarter, and analysts are predicting that it will be -3.67 at the market close of one year from today.
Technical Analysis of Dianthus Therapeutics Inc (DNTH)
Through scrutinizing the latest numbers posted by the [Dianthus Therapeutics Inc, DNTH], it can be observed that its last 5-days Average volume of 0.46 million was lower the volume of 0.46 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 32.53% While, its Average True Range was 44.92.
Raw Stochastic average of Dianthus Therapeutics Inc (DNTH) in the period of the previous 100 days is set at 86.03%, which indicates a major rise in contrast to 32.12% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.78 that was lower than 2.00 volatility it exhibited in the past 100-days period.
